SUPPLEMENT 1

Table S1. Duration of PASI90 days from baseline to week 52 (Sensitivity analysis assuming change in outcome occurred at the next available visit)

Duration of PASI90 during the study period (52 weeks)	Cohort A RISA only N = 895	Cohort B RISA and RISA/PBO N = 406	Cohort C ADA and ADA/RISA N = 303	Cohort D UST only N = 197	Cohort E PBO/RISA N = 300
Number of days, mean ± SD	242.31 ± 91.68	224.36 ± 100.07	175.77 ± 112.84	153.37 ± 121.67	138.02 ± 76.56
Proportion, mean ± SD	66% ± 25%	61% ± 27%	48% ± 31%	42% ± 33%	38% ± 21%

Abbreviations: ADA: adalimumab; PASI: Psoriasis Area and Severity Index; PBO: placebo; RISA: risankizumab; SD: standard deviation; UST: ustekinumab.

Figure S1. Sensitivity AUC analysis of PASI90 across study cohorts using LOCF imputation



Duration of PASI90 during the study period (52 weeks)	Cohort A RISA only N = 895	Cohort B[a] RISA and RISA/PBO N = 406	Cohort C[b] ADA and ADA/RISA N = 303	Cohort D UST only N = 197	Cohort E PBO/RISA N = 300
Number of days	252.96	232.46	188.29	157.29	159.31
Proportion	69%	64%	63%	43%	44%

Abbreviations: ADA: adalimumab; PASI: Psoriasis Area and Severity Index; PBO: placebo; RISA: risankizumab; UST: ustekinumab.

Notes:

[a] In Cohort B (RISA and RISA/PBO), 181 patients received RISA followed by RISA and 225 patients received RISA followed by PBO.
[b] In Cohort C (ADA and ADA/RISA), 212 patients received ADA followed by ADA and 91 patients received ADA followed by RISA.

Figure S2. Sensitivity AUC analysis of DLQI0/1 across study cohorts using LOCF imputation



Duration of DLQI0/1 during the study period (52 weeks)	Cohort A RISA only N = 898	Cohort B[a] RISA and RISA/PBO N = 0	Cohort C[b] ADA and ADA/RISA N = 304	Cohort D UST only N = 197	Cohort E[a] PBO/RISA N = 200
Number of days	218.84	N/A	162.15	149.52	91.84
Proportion	60%	N/A	44%	41%	25%

Abbreviations: ADA: adalimumab; DLQI: Dermatology Life Quality Index; PBO: placebo; RISA: risankizumab; UST: ustekinumab.

Notes:

[a] Patients from IMMhance trial did not collect DLQI data after week 16 and thus were excluded from the analysis. This resulted in excluding Cohort B: RISA and RISA/PBO and a smaller sample of Cohort E.

[b] In Cohort C (ADA and ADA/RISA), 213 patients received ADA followed by ADA and 91 patients received ADA followed by RISA.